Pharmalive - The Pulse of the Pharmaceutical Industry
Search Criteria: Search In:  
Conferences


R&D Directions Insider

Benlysta nod should benefit remaining lupus prospects

Thursday, March 10th, 2011

FDA's approval of Benlysta is indeed an historic moment for lupus patients, a community that has waited 50 years for a new treatment. The milestone, however, may have even bigger ramifications going forward. The door for additional – and perhaps more effective – new drugs for the autoimmune disorder has suddenly ...

Posted in antibodies, clinical trials, drug discovery | No Comments »

Q&A: Steve Paul

Monday, January 25th, 2010

The interview appears here, as part of our annual January Top 10 Pipelines coverage.

Posted in Uncategorized | No Comments »

Prasugrel not pleasing

Wednesday, June 3rd, 2009

Since January 2008, FDA has been discussing the benefits over the risks of Eli Lilly’s prasugrel. The drug prevents more heart attacks than Plavix, but causes more internal bleeding, according to a study conducted by Lilly. Consumer health advocates and Dr. Victor Serebruany, who worked on the early development of ...

Posted in filed for approval | No Comments »

   
about us | advertise | contact us | home
terms of use | privacy | copyright | site map 		©2012 UBM Canon